The independent medical news service

High tumor mutational burden is associated with a better response to immune checkpoint inhibitors in people with non-small-cell lung cancer across all levels of PD-L1 expression, US researchers report.

Patients with advanced ALK-positive non-small-cell lung cancer derive prolonged progression-free survival from first-line treatment with lorlatinib regardless of the presence of brain metastases, post-hoc analyses indicate.

Ramucirumab plus pembrolizumab significantly improves overall survival versus standard of care in people with advanced non-small-cell lung cancer previously treated with immunotherapy and chemotherapy, phase 2 Lung-MAP Protocol substudy data show.

The neoadjuvant combination of nivolumab and chemotherapy elicits a significantly higher pathologic complete response rate than chemotherapy alone in people with resectable stage IIIA–B non-small-cell lung cancer, shows the phase 2 NADIM II study.

French researchers have identified an association between detectable plasma levels of acetaminophen and poor outcomes in people receiving immune checkpoint inhibitors for advanced cancer.

Adding tiragolumab to atezolizumab plus carboplatin and etoposide provides no additional progression-free or overall survival benefit to patients with untreated extensive-stage small-cell lung cancer, phase 3 study data show.

Fresh findings from the phase 1 CHRYSALIS and CHRYSALIS-2 trials have been presented at the 2022 ASCO Annual Meeting, adding support for the use of amivantamab in certain groups of patients with advanced non-small-cell lung cancer.

Overall survival with first-line chemoimmunotherapy may be similar to that with immunotherapy alone among patients with advanced non-small-cell lung cancer and PD-L1 expression levels of at least 50%, pooled study data suggest.

Cabozantinib in combination with atezolizumab has “encouraging” antitumor activity, while cabozantinib alone has “modest” activity, in people who have received prior immune checkpoint inhibitor treatment for advanced non-small-cell lung cancer, say trial investigators.

First-line treatment with the third-generation EGFR–tyrosine kinase inhibitor aumolertinib significantly improves progression-free survival relative to gefitinib in people with advanced non-small-cell lung cancer and sensitizing EGFR mutations, indicate Chinese trial data.

Antibiotic use is associated with poor survival outcomes in people receiving tyrosine kinase inhibitors for advanced non-small-cell lung cancer or melanoma, findings indicate.

Previously untreated patients with PD-L1-positive advanced non-small-cell lung cancer could benefit from the combination of tiragolumab plus atezolizumab, indicate phase 2 trial data.

Around a quarter of phase 3 randomized controlled trials for advanced cancer show an improvement in global quality of life and this is significantly linked to improvements in overall survival, Canadian researchers say.

Find out more about the recommendations on exercise, diet, and weight management here

Adding the PD-L1 inhibitor adebrelimab to first-line chemotherapy significantly extends overall survival for patients with extensive-stage small-cell lung cancer, Chinese investigators report.

Results of a large systematic review and meta-analysis show that people with cancer have a significantly greater risk for death from SARS-CoV-2 infection than their cancer-free peers, particularly if they have lung or hematologic cancer.

Individuals with limited-stage small-cell lung cancer could benefit from the addition of durvalumab to chemoradiotherapy, suggest early data.

Electronic patient-reported outcomes to monitor immune-related adverse events during immunotherapy for cancer is associated with a reduction in the incidence of serious adverse events, emergency department visits, and treatment discontinuations, and a better quality of life, research suggests.

Individuals with non-small-cell lung cancer and brain metastases may benefit from treatment with immune checkpoint inhibitors plus radiotherapy after neurosurgical resection, findings indicate.

The risk for neurologic adverse events is significantly lower with immune checkpoint inhibitors than with other cancer treatments, particularly chemotherapy, suggest results of a systematic review and meta-analysis.